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Objective: This study was undertaken to analyze longitudinal changes of retinal thickness and their predictive value as
biomarkers of disease progression in idiopathic Parkinson’s disease (iPD).
Methods: Patients with Lewy body diseases were enrolled and prospectively evaluated at 3 years, including patients
with iPD (n = 42), dementia with Lewy bodies (n = 4), E46K-SNCA mutation carriers (n = 4), and controls (n = 17). All
participants underwent Spectralis retinal optical coherence tomography and Montreal Cognitive Assessment, and Uni-
fied Parkinson’s Disease Rating Scale score was obtained in patients. Macular ganglion cell–inner plexiform layer com-
plex (GCIPL) and peripapillary retinal nerve fiber layer (pRNFL) thickness reduction rates were estimated with linear
mixed models. Risk ratios were calculated to evaluate the association between baseline GCIPL and pRNFL thicknesses
and the risk of subsequent cognitive and motor worsening, using clinically meaningful cutoffs.
Results: GCIPL thickness in the parafoveal region (1- to 3-mm ring) presented the largest reduction rate. The annual-
ized atrophy rate was 0.63μm in iPD patients and 0.23μm in controls (p < 0.0001). iPD patients with lower parafoveal
GCIPL and pRNFL thickness at baseline presented an increased risk of cognitive decline at 3 years (relative risk [RR]
= 3.49, 95% confidence interval [CI] = 1.10–11.1, p = 0.03 and RR = 3.28, 95% CI = 1.03–10.45, p = 0.045, respec-
tively). We did not identify significant associations between retinal thickness and motor deterioration.
Interpretation: Our results provide evidence of the potential use of optical coherence tomography–measured par-
afoveal GCIPL thickness to monitor neurodegeneration and to predict the risk of cognitive worsening over time in iPD.
ANN NEUROL 2021;89:165–176
Cognitive impairment is a common and highly dis-abling feature of Parkinson’s disease (PD). At diagno-
sis, mild cognitive impairment can be detected in 15 to
40% of PD patients, and 10 years after disease onset
dementia affects up to 70% of patients.1–4 Some patients
with aggressive phenotypes might suffer a more rapid cog-
nitive deterioration and earlier instauration of dementia,
but the lack of validated clinical biomarkers has made dif-
ficult the prediction of cognitive deterioration and the
development of potential neuroprotective agents.1,2 Such
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severe PD subtypes are believed to share clinical and path-
ologic commonalities with 2 other less common diffuse
Lewy body diseases (LBDs): dementia with Lewy bodies
(DLB) and PD associated with E46K mutation in the
α-synuclein gene (E46K-SNCA).3 Both entities are charac-
terized by a rapidly progressive clinical deterioration with
a marked cognitive impairment that precedes or coincides
with the onset of parkinsonian motor signs.4,5 PD patients
demonstrate frequent abnormalities in visual functions,
including low-contrast visual acuity, contrast sensitivity,
color and pattern discrimination, depth and movement
perception, and several higher order visuospatial
abilities.6–16 Interestingly, visuospatial impairment, one of
the earliest and most prominent clinical features of DLB
and E46K-SNCA patients, is a main predictor of global
cognitive decline in PD patients.17 Moreover, recent evi-
dence supports that visual tests might predict PD
dementia.18,19
In line with this, the atrophy of macular ganglion
cell–inner plexiform layer complex (GCIPL) measured with
optical coherence tomography (OCT) has been shown to
be a good marker of visual dysfunction in PD,20 but the
link between macular GCIPL thinning and overall cognitive
impairment is poorly understood. Retinal neu-
rodegeneration, neuronal loss, and anomalous α-synuclein
deposits within inner retinal layers are now well-known
pathological features of LBD patients.21 Several cross-
sectional studies using OCT have demonstrated that, com-
pared to age-matched controls, PD patients have an atrophy
of inner retina that seems to be associated with disease dura-
tion and motor disability.22 More recent publications have
shown that the thinning of macular GCIPL in PD is linked
to cognitive impairment in de novo patients23 and to the
risk of dementia.18 Interestingly, our group found that
visual dysfunction in PD is selectively associated with the
thinning of GCIPL in the 1- to 3-mm diameter ring area
around the fovea (parafoveal GCIPL),20 an OCT feature
that has also been identified in patients with idiopathic
rapid eye movement sleep behavior disorder—the earliest
(prodromal) phase of LBD.24 So far, only few OCT studies
have prospectively evaluated the progression of retinal thin-
ning in PD patients,25–27 and none has specifically looked
at the rate of macular GCIPL atrophy and its relationship
with disease worsening.
In this study, we aimed to evaluate longitudinally
the dynamics of retinal atrophy and visual deterioration in
PD and the ability of single-timepoint OCT measures and
visual tests to predict the risk of motor and cognitive
decline. Furthermore, as a strategy to identify PD patients
with worse prognosis, we jointly evaluated PD patients
together with a cohort of controls, DLB patients, and
E46K-SNCA carriers.
Subjects and Methods
Study Design and Participants
We enrolled 62 patients with LBDs in a 3-year prospective longi-
tudinal study, including patients with idiopathic PD (iPD;
n = 50), DLB patients (n = 8), E46K-SNCA carriers (n = 4), and
29 controls. A total of 50 LBD patients (n = 42 iPD, n = 4 DLB,
n = 4 E46K-SNCA) and 17 controls successfully completed year 3
of follow-up assessments. Twelve patients (19%) and 12 controls
(41%) were lost to follow-up; 4 DLB and 2 iPD subjects had
severe motor and cognitive worsening related to LBD, 2 iPD sub-
jects had hemorrhagic stroke, 1 iPD subject died of pneumonia,
2 iPD subjects developed ophthalmological exclusion conditions,
and 1 iPD subject and 12 controls missed scheduled appointments
by 12 months or more. Study participants consisted of a selected
cohort of patients and controls recruited between 2015 and 2018
in the Department of Neurology at Cruces University Hospital
and in the Biscay PD Association. Patients with iPD fulfilled
Parkinson’s UK Brain Bank criteria for the diagnosis of PD, and
patients with DLB had a diagnosis of probable DLB according to
the 2017 Fourth Consensus Report of the DLB Consortium. All
patients were studied in an on-medication condition to complete
all study assessments. Before study inclusion and at year 3 follow-
up, all subjects underwent a restrictive screening protocol to
exclude participants with relevant confounding factors potentially
influencing clinical outcomes or retinal OCT measures. The
screening protocol consisted of a comprehensive questionnaire on
comorbidities, an ophthalmological examination, and structural
brain neuroimaging with 3T magnetic resonance imaging. We
excluded any subject with history of severe smoking (>20 ciga-
rettes/day) or heavy alcohol use (>4 drinks/day for men or >3
drinks/day for women), diagnosis of any type or grade of diabetes,
uncontrolled or resistant elevated blood pressure, obesity (body
mass index > 30), history of consumption of drugs or medications
known to induce retinal toxicity or cognitive impairment, chronic
inflammatory systemic diseases (eg, lupus erythematosus, sarcoid,
Behçet’s disease), carotid or cerebral artery disease, moderate to
severe deep white matter cerebral small vessel disease (Fazekas
grade 2 or higher), or history of brain trauma or other structural
brain lesions or central nervous system diseases other than
PD. Patients with well-controlled high blood pressure (hyperten-
sion) without complications were included in the study. We also
excluded candidates with spherical equivalent refractive error
> 4.00 diopters, >3.00 diopters of astigmatism, or any other ocular
condition potentially affecting OCT measures, as detailed in
OSCAR-IB criteria.28 Lastly, to establish reference values for age-
related changes in macular OCT measurements, we used a dataset
of OCT images from 250 healthy volunteers. The study protocol
was approved by the regional Basque Clinical Research Ethics
Committee. All participants gave written informed consent prior
to their participation in the study, in accordance with the tenets of
the Declaration of Helsinki.
Demographical Features and PD-Related
Variables
Age at baseline and sex were recorded for all participants. Two
neurologists experienced in the field of movement disorders
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recorded disease duration, Hoehn & Yahr scale score, Unified
Parkinson’s Disease Rating Scale Part III (motor examination)
score (UPDRS III), and L-dopa equivalent daily dose (LEDD).
Cognitive and Visual Outcomes Assessment
General cognition was evaluated with the Montreal Cognitive
Assessment (MoCA).29,30 PD patients with severe cognitive dete-
rioration at baseline visit (MoCA < 14) were excluded from the
study. All visual function outcomes were obtained binocularly
with best-corrected refraction. We registered high-contrast visual
acuity and low-contrast visual acuity as the total number of let-
ters correctly identified in, respectively, standard Early Treatment
Diabetic Retinopathy Study (ETDRS) charts and Sloan 2.5%
charts (Precision Vision, La Salle, IL) mounted in a retro-
illuminated cabinet at 4m. Contrast sensitivity was measured
with a Pelli-Robson chart at 1m under photopic conditions
(280 lux), and the lowest contrast at which 2 letters in a triplet
were correctly identified was recorded. In addition, we performed
a detailed evaluation of visual cognition with tests including the
number of correct answers on the Salthouse Perceptual Compari-
son Test, Symbol Digit Modalities Test, Picture Completion
subtest of the Wechsler Adult Intelligence Scale IV, Benton
Judgement of Line Orientation Test (H-form at baseline, V-form
at follow-up), Number Location and Cube Analysis tests of the
Visual Object and Space Perception battery, inverse of the time
to complete Trail Making Test part A, and the score on the
Clock Drawing Test (Rouleau scoring method).
OCT Acquisition, Segmentation, and Processing
Macular and peripapillary OCT images were acquired for each
eye using Spectralis spectral-domain OCT (SD-OCT; Heidel-
berg Engineering, Heidelberg, Germany), and thickness measures
were calculated for peripapillary retinal nerve fiber layer
(pRNFL) and for different combinations of layers and regions of
the macula, as previously described20. Briefly, macular scans con-
sisted of 25 single horizontal axial scans covering a 20 × 20
area (512 A-scans per B-scan and 49 frames per B-scan). Peri-
papillary scans consisted of a 12 diameter ring scan manually
centered on the optic nerve head (768 A-scans per B-scan,
100 frames per B-scan). All OCT images fulfilled OSCAR-IB
quality control criteria.28 Baseline OCT images were selected as
reference with the Follow-up tool, which ensured identical posi-
tioning and scanning parameters at follow-up examinations.
Statistical Analysis
Statistical analysis was done in R (v3.6.1) and RStudio
(v1.2.1335). Group characteristics were compared using Fisher’s
exact test for categorical variables and Kruskal–Wallis test for
quantitative variables. For describing longitudinal progression of
OCT measurements, visual function, and cognitive and motor
parameters, multivariate linear mixed-effects regression models
(LMMs; lme4 package31) were used. Probability values were
obtained with the lmerTest package. Age and sex were used as
fixed effects and a random intercept for subjects, separately in
iPD patients and controls. To test for differences in retinal and
clinical variables between iPD patients and controls, an
interaction term between time and group was introduced. In
patients, LMM was further adjusted for the following con-
founding variables: disease duration at study inclusion, UPDRS
III score, LEDD, and diagnosis of hypertension. Loss to follow-
up in patients was assumed not to be random, because it was
probably associated with study outcomes. Accordingly, to reduce
estimate bias we also adjusted the LMM for the pattern of miss-
ing data (0 = observation at 2 timepoints; 1 = observation at
baseline and missing data at follow-up).
For predicting clinical outcome worsening from OCT-
derived and visual parameters, we first fitted linear models.
Restricted cubic splines analysis with 5 knots revealed a nonlinear
relationship between baseline retinal variables and disease-related
changes, which led us to calculate relative risks (RRs). For the lat-
ter, outcomes were categorized as follows. We used a 5-point
change in UPDRS III score as the clinically relevant change to
consider motor worsening.32,33 The score of MoCA was consid-
ered to have declined if there was a reduction of 4 points or more,
based on the upper limit of the lowest quartile of MoCA score
changes across 2 timepoints in LBD patients. Predictor categoriza-
tion was based on baseline measurements; we averaged baseline
z scores of low-contrast visual acuity and visual cognition tests in
LBD patients for classifying iPD patients into 2 groups using K-
means clustering,20 and including DLB and E46K-SNCA within
the classification as models. Also, iPD patients were categorized
into retinal thickness tertiles. The tertile cutoffs were selected using
as reference retinal thickness distribution of 250 controls aged
40 to 83 years. iPD patients below the 25th percentile were
assigned to the lowest thickness tertile (for parafoveal GCIPL:
72.1–89.7μm, for pRNFL: 83–92.5μm), patients in the inter-
quartile range were categorized as the intermediate tertile (par-
afoveal GCIPL: 89.7–98.9μm, pRNFL: 92.5–107μm), and
individuals above the 75th percentile were allocated to the highest
tertile (parafoveal GCIPL: 98.9–116μm, pRNFL: 107–125μm).
RRs were adjusted for baseline age, disease duration, sex, and
LEDD with robust Poisson regression models. Logistic regression
was used to test whether any baseline clinical variable was associ-
ated with motor or cognitive worsening.
Results
Demographics and Clinical Features of Study
Population at Baseline
The demographics and clinical characteristics of study par-
ticipants are detailed in Table 1. Briefly, DLB patients
were significantly older (Bonferroni-corrected p < 0.05).
Mean UPDRS III score was 27.6 in iPD, 10 points less
than in DLB. Cognitive impairment was more severe for
E46K-SNCA and DLB than for iPD, and MoCA score
was significantly lower in iPD than in controls
(Bonferroni-corrected p = 0.02). At study inclusion,
28.5% of iPD patients, 25% of E46K-SNCA patients,
and 62.5% of DLB patients had well-controlled hyperten-
sion and the majority of iPD participants (83.7%) were
akinetic-rigid subtype.
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Visual outcomes at baseline were worse in iPD
patients compared to controls (Fig 1A), and overall, visual
impairment was more severe in E46K-SNCA and DLB
patients (see Table 1). According to baseline visual out-
comes, iPD patients were phenotypically classified into
2 groups using K-means clustering. The first group, the
“moderate to severe visual dysfunction” group, included
16 iPD patients (32%), 7 DLB patients, and 3 symptom-
atic E46K-SNCA carriers, whereas the second group, the
“mild visual dysfunction” group, included 34 iPD patients
(68%), 1 DLB patient, and 1 asymptomatic E46K-SNCA
mutation carrier.
OCT measures at study inclusion showed that, in
the central 3mm of the macula, GCIPL was signifi-
cantly thinner in DLB compared to iPD and controls,
and inner nuclear layer (INL) thickness was signifi-
cantly lower in E46K-SNCA carriers than in iPD. The
difference was largest in the parafoveal area (GCIPL:
DLB vs iPD, −9.6μm; DLB vs control, −10.7μm;
INL: E46K-SNCA vs iPD, −4.25μm; E46K-SNCA vs
TABLE 1. Baseline Demographics and Clinical Characteristics
Characteristic Control iPD E46K-SNCA DLB
n 29 50 4 8
Demographics
Age, yr 59.8 (7.1) 60.6 (8.3) 57.6 (5.3) 73.9 (7.3)
Sex, % female 58.6 36.7 50 25
PD-related features
Disease duration, yr NA 6.5 (4.0) 8.8 (5.1) 8.0 (5.8)
Age at disease onset NA 54.0 (7.8) 48.8 (6.6) 66.0 (9.6)
HY score, median (IQR) NA 2 (2–2.5) 2.5 (1.9–2.6) 2.5 (2.5–3)
UPDRS III score NA 27.6 (11.1) 28.3 (20.3) 37.1 (13.7)
LEDD NA 677.5 (399.1) 800.4 (701.6) 514.1 (329.7)
Cognitive status
MoCA score 26.6 (3.3) 24.3 (3.2) 19.0 (7.0) 17.6 (7.5)
Visual outcomes
High-contrast VA, correct letters, n 61.6 (4.2) 58.8 (5.7) 52.8 (3.6) 48.4 (12.1)
Low-contrast VA, correct letters, n 38.0 (6.2) 27.5 (12.0) 11.5 (13.9) 15.4 (11.6)
Contrast sensitivity, logCS 2.0 (0.1) 1.9 (0.1) 1.8 (0.1) 1.8 (0.2)
Trail Making Test part A, s 45.0 (17.7) 53.9 (23.2) 77.7 (21.4) 77.7 (19.4)
Symbol Digit Modality Test 46.6 (10.9) 34.2 (14.3) 20.0 (15.6) 17.0 (7.0)
Salthouse Perceptual Comparison Test 25.6 (7.8) 23.3 (9.3) 11.0 (9.0) 9.6 (4.8)
Benton Judgement Line Orientation 23.9 (3.9) 20.3 (5.9) 16.0 (10.4) 18.3 (2.5)
WAIS IV, Picture Completion 11.5 (3.8) 8.8 (4.2) 5.8 (3.6) 6.0 (3.5)
VOSP, Number Location 9.0 (1.8) 8.3 (2.0) 7.3 (2.2) 8.0 (0.9)
VOSP, Cube Analysis 9.7 (0.7) 8.7 (2.0) 5.3 (3.3) 7.0 (3.9)
Clock Drawing Test 9.1 (1.3) 7.8 (2.0) 3.8 (2.9) 7.0 (2.5)
Results are displayed as mean (standard deviation), except for sex and HY score, which are shown as indicated.
DLB = patients with dementia with Lewy bodies; E46K-SNCA = E46K mutation carriers of α-synuclein gene; HY = Hoehn & Yahr scale; iPD = idio-
pathic Parkinson disease; IQR = interquartile range; LEDD = L-dopa equivalent daily dose; MoCA = Montreal Cognitive Assessment; PD = Parkinson
disease; UPDRS III = motor part of Unified Parkinson’s Disease Rating Scale; VA = visual acuity; VOSP = Visual Object and Space Perception battery;
WAIS IV = Wechsler Adult Intelligence Scale, 4th edition.
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controls, −3.27μm). Bonferroni-corrected pairwise
comparisons were nonsignificant for the remaining
thickness parameters of the macula and pRNFL.
At baseline, parafoveal thickness of GCIPL and
INL in iPD were significantly correlated with MoCA
score and UPDRS III score (Fig 2A), correlation coeffi-
cients being slightly higher for GCIPL than for INL.
Cognitive and motor scores were not correlated in iPD
patients, although the relationship was significant when
akinetic-rigid iPD subtype was separately analyzed
(r = −0.36, p = 0.021).
Progression of Motor, Cognitive, and Visual
Impairment after 3 Years of Follow-up
From the 50 LBD patients who completed follow-up visit,
17 patients (34%; 14 iPD, 1 DLB, and 2 E46K-SNCA)
suffered a clinically relevant motor progression (Δ UPDRS
III ≥ 5 points). Motor worsening was not associated with
any baseline clinical variable, except for baseline UPDRS
III score (odds ratio = 0.897, p = 0.016), whereby per 1-
unit increase in the initial UPDRS III score the odds of
having an increase of 5 points or more in UPDRS III at
3 years decreased by a factor of 0.90.
FIGURE 1: Visual outcomes. (A) Differences in baseline visual outcomes between controls and idiopathic Parkinson disease (iPD)
patients. Significant differences are indicated with asterisks (Wilcoxon rank sum test, *p < 0.05, **p < 0.01, ***p < 0.001).
(B) Longitudinal changes in visual outcomes. Relative changes (percentage) of visual outcomes were calculated as ([follow-up
visual score – baseline visual score] / baseline visual score) × 100. #p < 0.05 for the interaction term between group and time in
linear mixed models. Note that the results of n = 50 iPD patients and n = 29 controls are represented in A and the results of
n = 42 iPD patients and n = 17 controls in B. BLOJ = Benton Line Orientation Judgment; CA = cube analysis subitem;
CDT = Clock Drawing Test, reproduction, corrected with Rouleau method; CS = contrast sensitivity; HCVA = high-contrast visual
acuity (number of correct letters); LCVA = low-contrast visual acuity (number of correct letters); NL = number location subitem;
SDMT = Symbol Digit Modality Test; SPCT = Salthouse Perceptual Comparison Test; TMT, part-A (s) = time to complete Trail
Making Test, part A, in seconds; VOSP = Visual Object and Space Perception battery; WAIS = figure completion part of
Wechsler Adult Intelligence Scale IV. [Color figure can be viewed at www.annalsofneurology.org]
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Regarding the progression of cognitive disability,
iPD patients showed a significant decrease in the mean
MoCA score (from 24.8 to 23.3; LMM, p = 0.01),
whereas in controls it slightly increased from 26.8 to
27.6 (LMM, p = 0.360). The decrease in the MoCA
score was more pronounced for E46K-SNCA (from 19.0
to 15.5) and DLB (from 24.0 to 16.0) than for iPD. At
follow-up, 8 iPD (19%), 4 DLB (100%), and 1 E46K-
SNCA subject (25%) presented a worsening of 4 points
or more on MoCA. Interestingly, cognitive worsening
was not associated with initial MoCA score or any other
demographic or disease-related clinical variable.
Although primary visual functions were clearly
affected at baseline in iPD patients as compared to con-
trols, the dynamics of the relative changes were similar,
and we found only small differences over time (see Fig 1B).
Clinically significant worsening of high-contrast visual
acuity (loss of 5 or more letters, corresponding to
1 logMAR line of ETDRS chart) was observed in 2.5% of
iPD patients, with no significant differences when com-
pared to controls. The decrease in low-contrast visual acu-
ity of 5 letters or more was present in a higher percentage
of participants, but in a similar proportion between of
iPD patients (20%) and controls (29.4%, p = 0.67), and
differences in annualized changes were not statistically sig-
nificant (LMM, group × time, p = 0.781). Intriguingly,
the rate of low-contrast visual acuity deterioration was
more prominent in the E46K-SNCA and DLB groups (%
change, −37.4 and −20.5, respectively) than in iPD
patients or controls. In iPD patients, median contrast
FIGURE 2: (A) Scatterplots represent the relationship between ganglion cell–inner plexiform layer complex (GCIPL) thickness in
the parafoveal area (1- to 3mm) and Montreal Cognitive Assessment (MoCA) and Unified Parkinson Disease Rating Scale Part III
(motor examination; UPDRS III) scores at baseline. (B) Progression of cognitive and motor manifestations. Parameter estimates
from linear mixed-effect models were converted to and plotted as condition means and standard error. Idiopathic Parkinson
disease (iPD) patients were divided into subgroups according to baseline thickness in the parafoveal area (1- to 3mm ring) of
GCIPL in the macula, baseline peripapillary retinal nerve fiber layer (pRNFL) thickness, and baseline visual outcomes. Retinal
thicknesses of iPD patients were divided into tertiles according to the reference population, and visual impairment was
determined using K-means clustering (see Subjects and Methods). Eleven iPD patients from the lowest retinal thickness tertile
and 31 iPD patients from the intermediate and highest tertiles completed a follow-up visit. Thirty-one patients who were
classified as mild visual dysfunction and 11 classified as moderate to severe visual dysfunction completed the 3-year visit.
r = Pearson correlation coefficient. [Color figure can be viewed at www.annalsofneurology.org]
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sensitivity decreased from 1.90 to 1.77 logCS at follow-up
(LMM, p < 0.001), whereas in controls the median of
2.10 logCS did not change, although the difference in the
rate of contrast sensitivity change was not statistically sig-
nificant (LMM, group × time, p = 0.06). Regarding visual
cognition tests, we failed to find within-group significant
changes at follow-up, except for Symbol Digit Modality
Test in controls (annualized estimate, −1.5; p = 0.014).
However, we found a significant interaction effect of time
and group for Benton Line Orientation Judgement
(LMM, p = 0.04), and Salthouse Perceptual Comparison
Test (LMM, p = 0.03; see Fig 1B).
Increased Rate of GCIPL and pRNFL Thinning in
iPD Patients
Using LMM analysis adjusted for age at baseline and sex,
we detected a distinct rate of macular GCIPL atrophy
between iPD patients and controls (Fig 3). In the control
group, the annualized estimates of GCIPL thickness were
−0.33μm in the 6mm disc, −0.19μm in the central 3mm
disc, and +0.07μm in the central 1mm disc. Addition-
ally, when the annualized GCIPL estimates were calcu-
lated in controls for rings around the fovea, a decrease
of −0.23μm was found in the 1- to 3mm (parafoveal)
ring and −0.37μm in the 3- to 6mm perifoveal ring
(Table 2). In iPD patients, the annual rate of atrophy
was largest in the parafoveal ring (−0.67μm), which
was 2 times greater than in controls and statistically sig-
nificant (LMM, group × time, p = 0.007). Similarly,
the overall thickness loss in 3mm disc (−0.63μm) was
also significant and significantly higher than in controls
(LMM, group × time, p = 0.005), as well as within the
central 1mm disc (−0.24μm; LMM, group × time,
p = 0.045). However, the rate of thinning in the 6mm
disc (−0.51μm) and 3- to 6mm perifoveal ring
(−0.47μm) was not significantly different in iPD
patients compared to controls. These estimates slightly
increased after adjusting for age and disease duration at
baseline, sex, UPDRS III score, LEDD, hypertension,
and missing data pattern (see Table 2). When other
FIGURE 3: Progression of retinal atrophy in peripapillary peripapillary retinal nerve fiber layer (pRNFL), and in 5 layer complexes
of the macula divided in 1mm, 1- to 3mm, and 3- to 6mm areas. The 1- to 3mm area corresponds to the parafoveal area of the
macula. Estimated changes of macular and peripapillary thickness between baseline and year 3 follow-up, adjusted for age and
sex, are displayed, and negative values represent retinal thinning over time. ELM-BM = retinal complex including external
limiting membrane, ellipsoid band, retinal pigment epithelium, and Bruch membrane; ETDRS = Early Treatment Diabetic
Retinopathy Study; GCIPL = ganglion cell–inner plexiform layer complex; I = inferior; INL = inner nuclear layer of the retina; iPD
= idiopathic Parkinson disease; mRNFL, macular retinal nerve fiber layer; N = nasal; OPL-HF-ONL = outer plexiform–Henle fiber–
outer nuclear layer complex; S = superior; T = temporal. [Color figure can be viewed at www.annalsofneurology.org]
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macular layers were evaluated using LMM, we only
observed statistically significant changes for outer
plexiform–Henle fiber–outer nuclear layer complex in
iPD patients, with a thinning ranging from −0.39 to
−0.25μm, but this thinning rate was not statistically
different from that observed in controls. The average
pRNFL thickness also decreased significantly over time
in iPD patients (−0.55μm/yr, p < 0.001) but not in
controls (−0.15μm/yr, p = 0.192; LMM, group × time,
p = 0.015; see Table 2).
Prediction of Disease Worsening from Retinal
OCT and Visual Function Parameters
Our results showed that iPD patients in the lowest par-
afoveal GCIPL thickness tertile at baseline had increased
adjusted RR of cognitive worsening compared with those
in higher tertiles (RR = 3.49, 95% confidence interval
[CI] = 1.10–11.11, p = 0.03). On the other hand, the risk
of motor worsening of iPD patients based on baseline par-
afoveal GCIPL thickness was not significant (RR = 0.63,
95% CI = 0.57–6.18, p = 0.566). Similarly, the RR of
TABLE 2. Linear Mixed-Model Effects Estimate of Annualized Atrophy of GCIPL and pRNFL
Model
iPD Control
iPD vs Control, pbEstimate SE pa Estimate SE pa
Model 1
yij = {
GCIPL 1–3mm −0.67 0.09 <0.001 −0.23 0.10 0.035 0.007
GCIPL 3–6mm −0.47 0.06 <0.001 −0.37 0.12 0.006 0.443
GCIPL 1mm −0.24 0.08 0.008 0.07 0.12 0.532 0.045
GCIPL 3mm −0.63 0.09 <0.001 −0.19 0.10 0.063 0.005
GCIPL 6mm −0.51 0.06 <0.001 −0.33 0.10 0.005 0.125




GCIPL 1–3mm −0.76 0.10 <0.0001
GCIPL 3–6mm −0.52 0.07 <0.0001
GCIPL 1mm −0.32 0.09 0.001
GCIPL 3mm −0.71 0.09 <0.0001
GCIPL 6mm −0.56 0.06 <0.0001
pRNFL −0.64 0.10 <0.0001
}
Six independent LMMs were fitted within each model. In model 1, the retinal variable yij for subject i and j-th timepoint was introduced as the out-
come variable, and years to follow-up, age, and sex as fixed effects, in addition to a random intercept for subjects, therefore represented by
yij = β0 + β1years to follow − upij + β2ageij + β3sexij + b0i + ϵij. In model 2, the same retinal variables as in model 1 were modeled using as fixed effects
years to follow-up, age, sex, baseline disease duration, UPDRS III score, LEDD, hypertension, and a random intercept for subjects, therefore expressed
by yij = β0 + β1 years to follow − upij + β2 ageij + β3 sexij + β4 disease durationij + β5 UPDRS IIIij + β6LEDD + + β7hypertension + β8lost to follow − up





Model 2 is only applicable to patients.
aProbability values represent the significance of within-group progression of retinal thinning.
bProbability values of the interaction term between years to follow-up and group in LMM.
GCIPL = ganglion cell–inner plexiform layer complex; iPD = idiopathic Parkinson disease; LEDD = L-dopa equivalent daily dose; LMM = linear
mixed-effects regression model; pRNFL = peripapillary nerve fiber layer; SE = standard error; UPDRS III = Unified Parkinson Disease Rating Scale
Part III (motor examination).
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cognitive decline between patients in the lowest pRNFL
tertile compared to patients in the intermediate and
highest pRNFL tertiles was significant (RR = 3.28, 95%
CI = 1.03–10.45, p = 0.045), but not for motor deteriora-
tion (RR = 1.91, 95% CI = 0.75–4.90, p = 0.193). When
patients were classified according to their visual outcomes
at baseline, the risk of general cognition worsening was
almost 5 times greater for patients with visual dysfunction
(RR = 4.69, 95% CI = 1.34–16.5, p = 0.01), even after
adjusting for confounders (RR = 4.79, 95% CI = 0.91–
21.18, p = 0.06). Conversely, the risk of motor deteriora-
tion was not different for patients with and without initial
visual impairment (adjusted RR = 1.15, 95% CI = 0.36–
3.61, p = 0.242).
Discussion
To the best of our knowledge, this is the first prospective
longitudinal study to investigate the rate of GCIPL and
pRNFL thinning over time in iPD patients using SD-
OCT, and the first to show that GCIPL thickness mea-
sured by OCT at a single timepoint can be used as a
marker of subsequent worsening of general cognition.
Age-related reduction rate of GCIPL thickness in a
healthy population has been measured in previous OCT
studies, with estimated annual thinning up to 0.25μm in
cross-sectional studies and 0.19 to 0.32μm in longitudinal
studies,34,35 which is in line with the annual decrease of
0.33μm that we found for the control group in our study.
However, the progression of disease-related retinal thin-
ning in iPD has not been extensively explored. Previous
studies investigating longitudinal retinal changes in PD
have only evaluated total macular volume or average
pRNFL thickness.25–27 In a prospective 5-year follow-up
study, Satue et al26 reported for the first time that macular
thinning in PD patients was greater than in controls, find-
ing the largest differences in inner nasal (−8.21μm), outer
inferior (−7.85μm), and inner temporal (−6.87μm) mac-
ular sectors. These authors also reported that, compared to
controls, pRNFL thickness reduction was significantly
higher in temporal and superotemporal sectors (3–4μm
thinning). Later, Ma et al27 found in a study of 22 PD
patients that macular thickness decreased 7μm and
pRNFL 6μm after 2.5 years of follow-up. A more recent
study evaluating 19 early stage PD patients found a mean
decrease in macular thickness of 7.4μm without significant
changes in pRNFL thickness after an average follow-up of
19 ± 8.5 months.25 In our study, pRNFL thickness reduc-
tion was almost 4 times greater in patients, with a compa-
rable annual thinning rate to that found by Satue et al.26
More importantly, according to our findings, the progres-
sion of GCIPL atrophy in the macula was 3 times greater
in iPD patients than in controls. Unfortunately, the lack
of longitudinal OCT studies evaluating GCIPL thinning
over time in PD renders it difficult to compare our
results.
Our findings revealed that iPD patients with lower
initial GCIPL and pRNFL thicknesses presented an
increased risk of cognitive decline at 3 years. Similarly,
iPD patients with visual dysfunction at baseline had
4 times the risk of global cognition deterioration at
follow-up. Furthermore, in our study, GCIPL and
pRNFL measurements were not associated with the pro-
gression of motor features. No significant differences were
observed in terms of age, sex, LEDD, disease duration,
and general cognition in patients with and without motor
progression, but lower UPDRS III score at baseline was
associated with motor progression. The pathophysiological
explanation for the observed relationship between the pro-
gression of cognitive decline and retinal atrophy and the
lack of association of the latter with the progression of
motor symptoms is intriguing. First, it is important to
bear in mind that visual stimuli are the main input for
most of the standard neuropsychological tests and that the
retina is the first processing station of visual information
in the central nervous system. Basic computations for the
analysis and interpretation of images, like edge detection,
are accomplished in the retina, where immunohistological
studies in PD have detected neuronal loss, synaptic and
dendritic abnormalities, and deposits of phosphorylated
α-synuclein, especially in ganglion cells.21 Although
abnormalities in perception and processing of visual infor-
mation in PD might be in part related to the injury of
cortical and subcortical areas of the brain,36–38 the
involvement of the retina in visual cognition abnormalities
of PD patients is firmly supported by several in vivo elec-
trophysiological and OCT studies.39 Our findings under-
pinning that visual dysfunction and macular GCIPL and
pRNFL atrophy can independently predict the progression
of cognitive disability in iPD are supported by the recent
publication by Leyland et al.18 Moreover, visual loss has
an impact on physical activity, mental stimulation, and
social interactions—factors reported to reduce the progres-
sion of cognitive impairment and the risk of dementia.40
Therefore, all the aforementioned aspects may contribute
to the effect of retinal injury and associated visual impair-
ment on future risk of dementia, as observed in the elderly
population.41,42 Finally, our findings showing a lack of
association between motor worsening and macular GCIPL
atrophy may suggest different pathophysiological mecha-
nisms underlying neurodegeneration of the retina and
brain structures involved in motor manifestations. To
date, only one neuroimaging study has evaluated in vivo
the relation between retinal thickness and the integrity of
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brain regions involved in motor manifestations of PD,
finding an association between inner retinal atrophy and
lower dopamine transporter uptake in substantia nigra.43
However, the majority of previous OCT studies in PD
failed to demonstrate statistically significant results or
yielded contradictory findings regarding the link between
retinal atrophy and motor disability or disease duration.22
Given that macular GCIPL atrophy has been reported in
de novo PD patients23 and in prodromal phases of LBD24
and the lack of its correlation with disease duration or
motor manifestations, it may suggest that retinal injury is
an early phenomenon of iPD. Nonetheless, the mecha-
nisms mediating the initiation and progression of retinal
thinning in iPD are unknown. Ortuño-Lizaran et al44
identified phosphorylated α-synuclein–reactive cells in the
retina of 9 postmortem PD patients and 4 patients with
incidental LBD. More recently, Shi et al45 observed that
retinal capillary complexity was decreased in the 2.5mm
annular zone that approximately coincides with the par-
afoveal region in which we found the largest retinal atro-
phy. In line with this, Kwapong et al46 found a
correlation between the impairment in the microvascula-
ture in that area and GCIPL thinning. However, the pre-
cise contribution of the microvasculature and α-synuclein
as a causal factor for inner retinal thinning remains chal-
lenging, and probably several nonidentified factors con-
tribute. Regardless of the cause, our study showed that
GCIPL thickness, mainly in the parafoveal region, and
pRNFL thickness in iPD patients decreased at a faster rate
than in the controls, and patients with lower baseline reti-
nal measures were at higher risk of suffering cognitive
decline.
Our study has some limitations. First, the CIs of the
estimated risk of our analyses are wide, probably as the
result of the sample size. Second, clinically significant
changes for UPDRS III have been reported in the litera-
ture, and a 5-point cutoff value is valid in clinical practice
for patients with Hoehn & Yahr scores I to III, as in our
sample.32,33 However, the clinically significant change for
MoCA score in iPD has not been stablished. We used a
4-point cutoff value based on the distribution of MoCA
changes in LBD patients, but this value may need to be
confirmed in future studies. Another potential limitation
is that we did not consider the influence of non-
dopaminergic medications in cognitive and visual func-
tion. Also, loss to follow-up in patients was assumed not
to be random, which might have biased the estimates of
risk ratios. Therefore, our data should be interpreted with
caution. Despite these limitations, this study had many
strengths. Due to the prospective study design, we were
able to observe changes in GCIPL and pRNFL thickness
of iPD patients at 3 years. Moreover, mixed models were
used for controlling for within-patient correlations, and
missing data pattern was introduced in the models, which
is more robust for longitudinal data analysis than previ-
ously used statistical analyses. Finally, predictions of motor
and cognitive impairment from baseline OCT measures
have not been previously contemplated in iPD, and robust
Poisson models were used to provide unbiased estimates
of risk ratios.
In conclusion, this work represents the first prospec-
tive longitudinal OCT study investigating the rate of reti-
nal thinning over time in iPD patients and its relationship
with motor and cognitive outcomes. As the main findings,
we showed that after 3 years of follow-up the progression
of macular GCIPL and pRNFL atrophy was 3 to 4 times
greater in iPD patients than in controls and that retinal
thickness measured by OCT at a single timepoint could
be used as a potential marker of subsequent worsening of
general cognition in iPD. Future studies with larger sam-
ple sizes and more follow-up timepoints will be needed to
validate the suitability of macular GCIPL and pRNFL
thickness measurement with OCT for monitoring neu-
rodegeneration and as an imaging biomarker of cognitive
decline in iPD.
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